Clinical Trial Update: Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36) [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of aclidinium bromide in chronic obstructive pulmonary disease evaluated safety, tolerability, and efficacy; results from the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TUDORZA PRESSAIR (ACLIDINIUM BROMIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-09-14